Statin-induced mevalonate pathway inhibition attenuates the growth of mesenchymal-like cancer cells that lack functional E-cadherin mediated cell cohesion

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Warita, Katsuhiko ^a   Warita, Tomoko ^a   Beckwitt, Colin H ^a   Schurdak, Mark E ^a   Vazquez, Alexei ^b   Wells, Alan ^a   Oltvai, Zoltán N ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CADHERIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; TUMOR PROTEIN;

BIOSYNTHESIS; CELL ADHESION; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

CADHERINS; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; CHOLESTEROL; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MEVALONIC ACID; NEOPLASM PROTEINS; NEOPLASMS;

EID: 84941749301     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep07593     Document Type: Article

References (38)

1. Issa, N. T., Byers, S. W. & Dakshanamurthy, S. Drug repurposing: translational pharmacology, chemistry, computers and the clinic. Curr. Top. Med. Chem. 13, 2328-2336 (2013).
2. Stenvang, J. et al. Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug development. Front. Oncol. 3, 313, doi:10.3389/fonc.2013.00313 (2013).
3. Farwell, W. R. et al. The association between statins and cancer incidence in a veterans population. J. Natl. Cancer Inst. 100, 134-139, doi:10.1093/jnci/djm286 (2008).
4. Nielsen, S. F., Nordestgaard, B. G. & Bojesen, S. E. Statin use and reduced cancerrelated mortality. N. Engl. J. Med. 367, 1792-1802, doi:10.1056/NEJMoa1201735 (2012).
5. Ginestier, C. et al.Mevalonate metabolism regulates basal breast cancer stem cells and is a potential therapeutic target. Stem Cell 30, 1327-1337, doi:10.1002/ stem.1122 (2012).
6. Hartwell, K. A. et al.Niche-based screening identifies small-molecule inhibitors of leukemia stem cells. Nat. Chem. Biol. 9, 840-848, doi:10.1038/nchembio.1367 (2013).
7. Gazzerro, P. et al. Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol. Rev. 64, 102-146, doi:10.1124/pr.111.004994 (2012).
8. Osmak, M. Statins and cancer: current and future prospects. Cancer Lett. 324, 1-12, doi:10.1016/j.canlet.2012.04.011 (2012).
9. Clendening, J. W. & Penn, L. Z. Targeting tumor cell metabolism with statins. Oncogene 31, 4967-4978, doi:10.1038/onc.2012.6 (2012).
10. Budman, D. R., Tai, J. & Calabro, A. Fluvastatin enhancement of trastuzumab and classical cytotoxic agents in defined breast cancer cell lines in vitro. Breast Cancer Res. Treat. 104, 93-101, doi:10.1007/s10549-006-9395-5 (2007).
11. Campbell, M. J. et al. Breast cancer growth prevention by statins. Cancer Res. 66, 8707-8714, doi:10.1158/0008-5472.can-05-4061 (2006).
12. Levine, A. J. & Puzio-Kuter, A. M. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 330, 1340-1344, doi:10.1126/ science.1193494 (2010).
13. Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029-1033, doi:10.1126/science.1160809 (2009).
14. Li, F., Xu, W. & Zhao, S. Regulatory roles of metabolites in cell signaling networks. J. Genet. Genomics 40, 367-374, doi:10.1016/j.jgg.2013.05.002 (2013).
15. Venneti, S. & Thompson, C. B. Metabolic modulation of epigenetics in gliomas. Brain Pathol. 23, 217-221, doi:10.1111/bpa.12022 (2013).
16. Li, Y. C., Park, M. J., Ye, S. K., Kim, C. W. & Kim, Y. N. Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. Am. J. Pathol. 168, 1107-1118; doi:10.2353/ajpath.2006.050959 (2006).
17. Dolfi, S. C. et al. The metabolic demands of cancer cells are coupled to their size and protein synthesis rates. Cancer Metab. 1, 20, doi:10.1186/2049-3002-1-20 (2013).
18. Chaffer, C. L. & Weinberg, R. A. A perspective on cancer cell metastasis. Science 331, 1559-1564, doi:10.1126/science.1203543 (2011).
19. Shoemaker, R. H. The NCI60 human tumour cell line anticancer drug screen. Nat. Rev. Cancer 6, 813-823, doi:10.1038/nrc1951 (2006).
20. Ginsbach, C. & Fahimi, H. D. Labeling of cholesterol with filipin in cellular membranes of parenchymatous organs. Standardization of incubation conditions. Histochemistry 86, 241-248 (1987).
21. Chetty, R., Serra, S. & Asa, S. L. Loss of membrane localization and aberrant nuclear E-cadherin expression correlates with invasion in pancreatic endocrine tumors. Am. J. Surg. Pathol. 32, 413-419, doi:10.1097/PAS.0b013e31813547f8 (2008).
22. Han, A. C., Soler, A. P., Tang, C. K., Knudsen, K. A. & Salazar, H. Nuclear localization of E-cadherin expression in Merkel cell carcinoma. Arch. Pathol. Lab. Med. 124, 1147-1151, doi:10.1043/0003-9985 (2000).
23. Chao, Y., Wu, Q., Shepard, C. & Wells, A. Hepatocyte induced re-expression of Ecadherin in breast and prostate cancer cells increases chemoresistance. Clin. Exp. Metastasis 29, 39-50, doi:10.1007/s10585-011-9427-3 (2012).
24. Chao, Y. L., Shepard, C. R. & Wells, A. Breast carcinoma cells re-express Ecadherin during mesenchymal to epithelial reverting transition. Mol. Cancer 9, 179, doi:10.1186/1476-4598-9-179 (2010).
25. Yu, M. et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339, 580-584, doi:10.1126/ science.1228522 (2013).
26. Chao, Y., Wu, Q., Acquafondata, M., Dhir, R. & Wells, A. Partial mesenchymal to epithelial reverting transition in breast and prostate cancer metastases. Cancer Microenviron. 5, 19-28, doi:10.1007/s12307-011-0085-4 (2012).
27. Taylor, D. P., Wells, J. Z., Savol, A., Chennubhotla, C. & Wells, A. Modeling boundary conditions for balanced proliferation in metastatic latency. Clin. Cancer Res. 19, 1063-1070, doi:10.1158/1078-0432.ccr-12-3180 (2013).
28. Wells, A., Griffith, L., Wells, J. Z. & Taylor, D. P. The dormancy dilemma: quiescence versus balanced proliferation. Cancer Res. 73, 3811-3816, doi:10.1158/ 0008-5472.can-13-0356 (2013).
29. Zhao, B., Tumaneng, K. & Guan, K. L. The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat. Cell Biol. 13, 877-883, doi:10.1038/ncb2303 (2011).
30. Wang, Z. et al. Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility. Proc. Natl. Acad. Sci. USA. 111, E89-98, doi:10.1073/pnas.1319190110 (2014).
31. Sorrentino, G. et al. Metabolic control of YAP and TAZ by the mevalonate pathway. Nat. Cell Biol. 16, 357-366, doi:10.1038/ncb2936 (2014).
32. Pan, D. The hippo signaling pathway in development and cancer. Dev. Cell 19, 491-505, doi:10.1016/j.devcel.2010.09.011 (2010).
33. Bhat, K. P. et al. The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev. 25, 2594-2609, doi:10.1101/ gad.176800.111 (2011).
34. Cordenonsi, M. et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 147, 759-772, doi:10.1016/j.cell.2011.09.048 (2011).
35. Malenda, A. et al. Statins impair glucose uptake in tumor cells. Neoplasia 14, 311-323 (2012).
36. George, K. S. & Wu, S. Lipid raft: A floating island of death or survival. Toxicol. Appl. Pharmacol. 259, 311-319, doi:10.1016/j.taap.2012.01.007 (2012).
37. Jenkins, C. M., Yang, J., Sims, H. F. & Gross, R. W. Reversible high affinity inhibition of phosphofructokinase-1 by acyl-CoA: a mechanism integrating glycolytic flux with lipid metabolism. J. Biol. Chem. 286, 11937-11950, doi:10.1074/jbc.M110.203661 (2011).
38. Wheeler, S. E. et al. All-human microphysical model of metastasis therapy. Stem Cell Res. Ther. 4 Suppl 1, S11, doi:10.1186/scrt372 (2013).